{"id":943,"date":"2024-01-30T23:34:24","date_gmt":"2024-01-30T23:34:24","guid":{"rendered":"https:\/\/www.eye-connect.org\/namd\/?page_id=943"},"modified":"2026-04-14T18:28:29","modified_gmt":"2026-04-14T22:28:29","slug":"home2-2","status":"publish","type":"page","link":"https:\/\/www.eye-connect.org\/namd\/","title":{"rendered":"nAMD"},"content":{"rendered":"<section class=\"l-section wpb_row height_auto\"><div class=\"l-section-h i-cf\"><div class=\"g-cols vc_row via_grid cols_1 laptops-cols_inherit tablets-cols_inherit mobiles-cols_1 valign_middle type_default stacking_default\"><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\">\n\t\t\t<!-- START nAMD Slider 2 REVOLUTION SLIDER 6.7.41 --><p class=\"rs-p-wp-fix\"><\/p>\n\t\t\t<rs-module-wrap id=\"rev_slider_2_1_wrapper\" data-source=\"gallery\" style=\"visibility:hidden;background:transparent;padding:0;margin:0px auto;margin-top:0;margin-bottom:0;\">\n\t\t\t\t<rs-module id=\"rev_slider_2_1\" style=\"\" data-version=\"6.7.41\">\n\t\t\t\t\t<rs-slides style=\"overflow: hidden; position: absolute;\">\n\t\t\t\t\t\t<rs-slide style=\"position: absolute;\" data-key=\"rs-2\" data-title=\"Slide\" data-in=\"o:0;\" data-out=\"a:false;\">\n\t\t\t\t\t\t\t<img decoding=\"async\" src=\"\/\/www.eye-connect.org\/namd\/wp-content\/plugins\/revslider\/sr6\/assets\/assets\/dummy.png\" alt=\"Slide\" title=\"nAMD\" class=\"rev-slidebg tp-rs-img rs-lazyload\" data-lazyload=\"\/\/www.eye-connect.org\/namd\/wp-content\/plugins\/revslider\/sr6\/assets\/assets\/transparent.png\" data-no-retina>\n<!--\n\t\t\t\t\t\t\t--><rs-layer\n\t\t\t\t\t\t\t\tid=\"slider-2-slide-2-layer-0\" \n\t\t\t\t\t\t\t\tdata-type=\"image\"\n\t\t\t\t\t\t\t\tdata-rsp_ch=\"on\"\n\t\t\t\t\t\t\t\tdata-xy=\"yo:-107px,-88px,-66px,-40px;\"\n\t\t\t\t\t\t\t\tdata-text=\"w:normal;s:20,16,12,7;l:0,20,15,9;\"\n\t\t\t\t\t\t\t\tdata-dim=\"w:[&#039;100%&#039;,&#039;100%&#039;,&#039;100%&#039;,&#039;100%&#039;];h:[&#039;100%&#039;,&#039;100%&#039;,&#039;100%&#039;,&#039;100%&#039;];\"\n\t\t\t\t\t\t\t\tdata-basealign=\"slide\"\n\t\t\t\t\t\t\t\tdata-frame_999=\"o:0;st:w;\"\n\t\t\t\t\t\t\t\tstyle=\"z-index:6;\"\n\t\t\t\t\t\t\t><img decoding=\"async\" src=\"\/\/www.eye-connect.org\/namd\/wp-content\/plugins\/revslider\/sr6\/assets\/assets\/dummy.png\" alt=\"\" class=\"tp-rs-img rs-lazyload\" width=\"1240\" height=\"515\" data-lazyload=\"\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2024\/01\/retina-mosaic-header03.png\" data-c=\"cover-proportional\" data-no-retina> \n\t\t\t\t\t\t\t<\/rs-layer><!--\n\n\t\t\t\t\t\t\t--><rs-layer\n\t\t\t\t\t\t\t\tid=\"slider-2-slide-2-layer-2\" \n\t\t\t\t\t\t\t\tdata-type=\"text\"\n\t\t\t\t\t\t\t\tdata-color=\"#fff\"\n\t\t\t\t\t\t\t\tdata-rsp_ch=\"on\"\n\t\t\t\t\t\t\t\tdata-xy=\"xo:571px,513px,447px,181px;yo:133px,77px,64px,37px;\"\n\t\t\t\t\t\t\t\tdata-text=\"w:normal;s:30,24,18,16;l:35,28,23,20;ls:2,1,0,0;fw:600;a:right;\"\n\t\t\t\t\t\t\t\tdata-dim=\"w:571px,471px,306px,276px;h:134px,108px,91px,79px;minh:0,none,none,none;\"\n\t\t\t\t\t\t\t\tdata-margin=\"t:15,12,9,6;r:15,12,9,6;b:15,12,9,6;l:15,12,9,6;\"\n\t\t\t\t\t\t\t\tdata-padding=\"t:10,8,7,5;r:15,12,10,8;\"\n\t\t\t\t\t\t\t\tdata-frame_999=\"o:0;st:w;\"\n\t\t\t\t\t\t\t\tstyle=\"z-index:7;background-color:#351f65;font-family:'Verdana', 'Geneva', 'sans-serif';\"\n\t\t\t\t\t\t\t>New Anti-VEGF Therapies for Neovascular Age-related <br \/>\nMacular Degeneration \n\t\t\t\t\t\t\t<\/rs-layer><!--\n-->\t\t\t\t\t<\/rs-slide>\n\t\t\t\t\t<\/rs-slides>\n\t\t\t\t<\/rs-module>\n\t\t\t\t<script>\n\t\t\t\t\tsetREVStartSize({c: 'rev_slider_2_1',rl:[1240,1024,778,480],el:[375,300,275,250],gw:[1240,1024,778,480],gh:[375,300,275,250],type:'standard',justify:'',layout:'fullwidth',mh:\"0\"});if (window.RS_MODULES!==undefined && window.RS_MODULES.modules!==undefined && window.RS_MODULES.modules[\"revslider21\"]!==undefined) {window.RS_MODULES.modules[\"revslider21\"].once = false;window.revapi2 = undefined;if (window.RS_MODULES.checkMinimal!==undefined) window.RS_MODULES.checkMinimal()}\n\t\t\t\t<\/script>\n\t\t\t<\/rs-module-wrap>\n\t\t\t<!-- END REVOLUTION SLIDER -->\n<div class=\"w-separator size_small\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"font-size: 18px; color: #53565a;\">\n<p>This <strong>American Academy of Ophthalmology <\/strong>collection of activities provides ophthalmologists with a focused update on the latest data surrounding long-acting intravitreal anti-vascular endothelial growth factor (VEGF) therapies for neovascular age-related macular degeneration (nAMD). Click on the activities below to explore valuable insights and clinical decision-making around:<\/p>\n<ul style=\"line-height: 120%;\">\n<li>Therapy selection based on patient characteristics and disease progression<\/li>\n<li>Individualized dosing strategies and treatment intervals<\/li>\n<li>Monitoring response and adjusting therapy to reduce treatment burden<\/li>\n<\/ul>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_small\"><\/div><\/div><\/div><\/div><\/div><\/section><section class=\"l-section wpb_row us_custom_308d0844 height_auto\"><div class=\"l-section-h i-cf\"><div class=\"g-cols vc_row via_grid cols_1 laptops-cols_inherit tablets-cols_inherit mobiles-cols_1 valign_top type_default stacking_default\" style=\"--columns-gap:25px;\"><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-separator size_small\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"font-size: 24px; color: #332463;\">Featured Activities<\/div>\n<\/div><\/div><div class=\"w-separator size_small\"><\/div><div class=\"g-cols wpb_row namd-grid-4-2-1 via_grid cols_4 laptops-cols_inherit tablets-cols_inherit mobiles-cols_1 valign_top type_default stacking_default\" style=\"--columns-gap:20px;\"><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1345-2\/\" aria-label=\"A1345-Activity2-Thumbnail-Ver3\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity2-Thumbnail-Ver3-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Safety of the New Anti-VEGF Therapies: Findings From Treatment of nAMD\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity2-Thumbnail-Ver3-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity2-Thumbnail-Ver3-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity2-Thumbnail-Ver3.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"margin-bottom: 40px; color: #53565a; line-height: 130%;\"><a href=\"https:\/\/www.eye-connect.org\/namd\/1345-2\/\" target=\"_blank\" rel=\"noopener\"><u>Safety of the New Anti-VEGF Therapies<\/u><\/a><\/p>\n<p style=\"line-height: 120%; margin-bottom: 5px;\">Webinar<br \/>\nCredit Hours: 0.75 (45 min)<\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1345-2\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1345-5\/\" aria-label=\"A1345-Activity5-Thumbnail-Ver3\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity5-Thumbnail-Ver3-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Switching to a New Anti-VEGF Agent for nAMD\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity5-Thumbnail-Ver3-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity5-Thumbnail-Ver3-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity5-Thumbnail-Ver3.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"margin-bottom: 20px; color: #53565a; line-height: 130%;\"><a href=\"https:\/\/www.eye-connect.org\/namd\/1345-5\/\" target=\"_blank\" rel=\"noopener\"><u>Switching to a New Anti-VEGF Agent for nAMD<\/u><\/a><\/p>\n<p style=\"line-height: 120%; margin-bottom: 5px;\">Patient Simulation<br \/>\nCredit Hours: 0.25 (15 min)<\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1345-5\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1345-4\/\" aria-label=\"A1345-Activity4-Thumbnail-Ver3\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity4-Thumbnail-Ver3-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Initiating New Anti-VEGF Therapies in Patients With nAMD\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity4-Thumbnail-Ver3-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity4-Thumbnail-Ver3-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity4-Thumbnail-Ver3.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"margin-bottom: 20px; color: #53565a; line-height: 130%;\"><a href=\"https:\/\/www.eye-connect.org\/namd\/1345-4\/\" target=\"_blank\" rel=\"noopener\"><u>Initiating New Anti-VEGF Therapies in Patients With nAMD<\/u><\/a><\/p>\n<p style=\"line-height: 120%; margin-bottom: 5px;\">Patient Simulation<br \/>\nCredit Hours: 0.25 (15 min)<\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1345-4\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1345-1\/\" aria-label=\"A1345-Activity1-Thumbnail-Ver3\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity1-Thumbnail-Ver3-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Translating the Latest Data for New Intravitreal Anti-VEGF Therapies to Treat nAMD in Clinical Practice\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity1-Thumbnail-Ver3-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity1-Thumbnail-Ver3-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity1-Thumbnail-Ver3.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"margin-bottom: 20px; color: #53565a; line-height: 130%;\"><a href=\"https:\/\/www.eye-connect.org\/namd\/1345-1\/\" target=\"_blank\" rel=\"noopener\"><u>Translating the Latest Data for New Intravitreal Anti-VEGF Therapies<\/u><\/a><\/p>\n<p style=\"line-height: 120%; margin-bottom: 5px;\">Webinar<br \/>\nCredit Hours: 0.75 (45 min)<\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1345-1\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><\/div><div class=\"w-separator size_small\"><\/div><div class=\"g-cols wpb_row via_grid cols_4 laptops-cols_inherit tablets-cols_inherit mobiles-cols_1 valign_top type_default stacking_default\" style=\"--columns-gap:20px;\"><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1345-3\/\" aria-label=\"A1345-Activity3-Thumbnail-Ver3\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity3-Thumbnail-Ver3-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Personalizing Treatment for nAMD Using New Anti-VEGF Therapies\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity3-Thumbnail-Ver3-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity3-Thumbnail-Ver3-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1345-Activity3-Thumbnail-Ver3.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"margin-bottom: 20px; color: #53565a; line-height: 130%;\"><a href=\"https:\/\/www.eye-connect.org\/namd\/1345-3\/\" target=\"_blank\" rel=\"noopener\"><u>Personalizing Treatment for nAMD Using New Anti-VEGF Therapies<\/u><\/a><\/p>\n<p style=\"line-height: 120%; margin-bottom: 5px;\">Webinar<br \/>\nCredit Hours: 0.75 (45 min)<\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1345-3\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1416-1\/\" aria-label=\"A1416-1-thumbnail-ver2\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-1-thumbnail-ver2-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Second-Generation Anti-VEGF Therapies for nAMD: From Clinical Trials to Practice\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-1-thumbnail-ver2-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-1-thumbnail-ver2-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-1-thumbnail-ver2.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"margin-bottom: 20px; color: #53565a; line-height: 130%;\"><a href=\"https:\/\/www.eye-connect.org\/namd\/1416-1\/\" target=\"_blank\" rel=\"noopener\"><u>Second-Generation Anti-VEGF Therapies for nAMD: From Clinical Trials to Practice<\/u><\/a><\/p>\n<p style=\"line-height: 120%; margin-bottom: 5px;\">Webinar<br \/>\nCredit Hours: 0.50 (30 min)<\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/1416-1\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><div target=\"_blank\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-3-thumbnail-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Switching IVT Anti-VEGF Agents for nAMD\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-3-thumbnail-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-3-thumbnail-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-3-thumbnail.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"margin-bottom: 20px; color: #53565a; line-height: 130%;\">Switching IVT Anti-VEGF Agents for nAMD: So Many Options, How to Choose?<\/p>\n<p style=\"line-height: 120%; margin-bottom: 5px;\">Webinar<br \/>\nCredit Hours: 0.50 (30 min)<\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_7 disabled\" href=\"#\"><span class=\"w-btn-label\">Coming Soon<\/span><\/a><\/div><\/div><\/div><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><div target=\"_blank\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-4-thumbnail-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-4-thumbnail-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-4-thumbnail-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-4-thumbnail.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"margin-bottom: 20px; color: #53565a; line-height: 130%;\">When and How to Prioritize Injection Burden<\/p>\n<p style=\"line-height: 120%; margin-bottom: 5px;\">Webinar<br \/>\nCredit Hours: 0.25 (15 min)<\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_7 disabled\" href=\"#\"><span class=\"w-btn-label\">Coming Soon<\/span><\/a><\/div><\/div><\/div><\/div><div class=\"w-separator size_small\"><\/div><div class=\"g-cols wpb_row via_grid cols_4 laptops-cols_inherit tablets-cols_inherit mobiles-cols_1 valign_top type_default stacking_default\" style=\"--columns-gap:20px;\"><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><div target=\"_blank\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-5-thumbnail-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Managing Retinal Fluid in Wet AMD\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-5-thumbnail-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-5-thumbnail-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-5-thumbnail.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"margin-bottom: 40px; color: #53565a; line-height: 130%;\">Managing Retinal Fluid in Wet AMD<\/p>\n<p style=\"line-height: 120%; margin-bottom: 5px;\">Webinar<br \/>\nCredit Hours: 0.25 (15 min)<\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_7 disabled\" href=\"#\"><span class=\"w-btn-label\">Coming Soon<\/span><\/a><\/div><\/div><\/div><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><div target=\"_blank\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-2-thumbnail-ver2-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Getting Into the Details About Managing nAMD\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-2-thumbnail-ver2-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-2-thumbnail-ver2-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2026\/04\/A1416-2-thumbnail-ver2.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"margin-bottom: 20px; color: #53565a; line-height: 130%;\">Did You Know? Getting Into the Details About Managing nAMD<\/p>\n<p style=\"line-height: 120%; margin-bottom: 5px;\">Patient Simulation<br \/>\nCredit Hours: 0.25 (15 min)<\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_7 disabled\" href=\"#\"><span class=\"w-btn-label\">Coming Soon<\/span><\/a><\/div><\/div><\/div><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><\/div><\/div><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><\/div><\/div><\/div><div class=\"w-separator hide_on_mobiles size_small\"><\/div><\/div><\/div><\/div><\/div><\/section><section class=\"l-section wpb_row height_small\"><div class=\"l-section-h i-cf\"><div class=\"g-cols vc_row via_grid cols_1 laptops-cols_inherit tablets-cols_inherit mobiles-cols_1 valign_top type_default stacking_default\" style=\"--columns-gap:25px;\"><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"font-size: 24px; color: #332463;\">Archived<\/div>\n<\/div><\/div><div class=\"w-separator size_small\"><\/div><div class=\"g-cols wpb_row via_grid cols_4 laptops-cols_inherit tablets-cols_2 mobiles-cols_2 valign_top type_default stacking_default\" style=\"--columns-gap:20px;\"><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/activity1\/\" aria-label=\"A1280-Thumbnail01\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail01-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Extending Treatment Durability With Next-Generation nAMD Therapies\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail01-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail01-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail01.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"line-height: 130%; margin-bottom: 37px;\"><u><a href=\"https:\/\/www.eye-connect.org\/namd\/activity1\/\" target=\"_blank\" rel=\"noopener\">Extending Treatment Durability With Next-Generation nAMD Therapies<\/a> <\/u><\/p>\n<p style=\"line-height: 120%; margin-top: 30px;\">Webinar<br \/>\nCredit Hours: 0.50 (30 min)<br \/>\n<span style=\"font-size: 14px; color: #ff0000; line-height: 120%;\">This activity has expired and is no longer available for credit<\/span><\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/activity1\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/accredited-activity-2-advances-in-imaging-namd\/\" aria-label=\"A1280-Thumbnail02\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail02-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Advances in Imaging nAMD and Approaches to Use of Long-Acting Anti-VEGF Therapies\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail02-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail02-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail02.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"margin-bottom: 20px; line-height: 130%;\"><u><a href=\"https:\/\/www.eye-connect.org\/namd\/accredited-activity-2-advances-in-imaging-namd\/\" target=\"_blank\" rel=\"noopener\">Advances in Imaging nAMD and Approaches to Use of Long-Acting Anti-VEGF Therapies<\/a><\/u><\/p>\n<p style=\"line-height: 120%;\">Infographic<br \/>\nCredit Hours: 0.50 (30 min)<br \/>\n<span style=\"font-size: 14px; color: #ff0000;\">This activity has expired and is no longer available for credit<\/span><\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/accredited-activity-2-advances-in-imaging-namd\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/adherence-persistence-with-durable-anti-vegf-therapies-for-namd\/\" aria-label=\"A1280-Thumbnail03\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail03-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Improving Adherence and Persistence With Durable Anti-VEGF Therapies for nAMD\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail03-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail03-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail03.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"line-height: 130%; margin-bottom: 37px;\"><a href=\"https:\/\/www.eye-connect.org\/namd\/adherence-persistence-with-durable-anti-vegf-therapies-for-namd\/\" target=\"_blank\" rel=\"noopener\"><u>Improving Adherence and Persistence With Durable Anti-VEGF Therapies for nAMD<\/u><\/a><\/p>\n<p style=\"line-height: 120%; margin-top: 30px;\">Case Consult<br \/>\nCredit Hours: 0.25 (15 min)<br \/>\n<span style=\"font-size: 14px; color: #ff0000; line-height: 120%;\">This activity has expired and is no longer available for credit<\/span><\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/adherence-persistence-with-durable-anti-vegf-therapies-for-namd\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/dosing-strategy-anti-vegf-therapy-for-namd\/\" aria-label=\"A1280-Thumbnail04\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail04-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"When to Start, When to Switch, and Dosing Strategy With Anti-VEGF Therapy\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail04-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail04-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail04.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"margin-bottom: 37px; line-height: 130%;\"><a href=\"https:\/\/www.eye-connect.org\/namd\/dosing-strategy-anti-vegf-therapy-for-namd\/\" target=\"_blank\" rel=\"noopener\"><u>When to Start, When to Switch, and Dosing Strategy With Anti-VEGF Therapy<\/u><\/a><\/p>\n<p style=\"line-height: 120%; margin-top: 30px;\">Case Consult<br \/>\nCredit Hours: 0.25 (15 min)<br \/>\n<span style=\"font-size: 14px; color: #ff0000; line-height: 120%;\">This activity has expired and is no longer available for credit<\/span><\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/dosing-strategy-anti-vegf-therapy-for-namd\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><\/div><div class=\"g-cols wpb_row via_grid cols_4 laptops-cols_inherit tablets-cols_inherit mobiles-cols_1 valign_top type_default stacking_default\" style=\"--columns-gap:20px;\"><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/extended-dosing-intervals-anti-vegf-therapies-for-namd\/\" aria-label=\"A1280-Thumbnail05\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail05-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Success With Extended Dosing Intervals of Anti-VEGF Therapies for nAMD\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail05-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail05-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail05.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"margin-bottom: 37px; line-height: 130%;\"><a href=\"https:\/\/www.eye-connect.org\/namd\/extended-dosing-intervals-anti-vegf-therapies-for-namd\/\" target=\"_blank\" rel=\"noopener\"><u>Success With Extended Dosing Intervals of Anti-VEGF Therapies for nAMD<\/u><\/a><\/p>\n<p style=\"line-height: 120%; margin-top: 30px;\">Case Consult<br \/>\nCredit Hours: 0.25 (15 min)<br \/>\n<span style=\"font-size: 14px; color: #ff0000; line-height: 120%;\">This activity has expired and is no longer available for credit<\/span><\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/extended-dosing-intervals-anti-vegf-therapies-for-namd\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/long-acting-anti-vegf-therapies\/\" aria-label=\"A1280-Thumbnail06\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail06-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Strategies to Reduce Vision Loss in nAMD Using Long-Acting Anti-VEGF Therapies\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail06-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail06-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail06.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"margin-bottom: 37px; line-height: 130%;\"><a href=\"https:\/\/www.eye-connect.org\/namd\/long-acting-anti-vegf-therapies\/\" target=\"_blank\" rel=\"noopener\"><u>Strategies to Reduce Vision Loss in nAMD Using Long-Acting Anti-VEGF Therapies<\/u><\/a><\/p>\n<p style=\"line-height: 120%; margin-top: 30px;\">Patient Simulation<br \/>\nCredit Hours: 0.50 (30 min)<br \/>\n<span style=\"font-size: 14px; color: #ff0000; line-height: 120%;\">This activity has expired and is no longer available for credit<\/span><\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/long-acting-anti-vegf-therapies\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><\/div><\/div><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><\/div><\/div><\/div><div class=\"w-separator size_small\"><\/div><div class=\"w-html\"><hr style=\"height:1px;border-width:0;color:#5d4c84;background-color:#5d4c84\"><\/div><\/div><\/div><\/div><\/div><\/section><section class=\"l-section wpb_row us_custom_308d0844 hide_on_default hide_on_laptops hide_on_tablets hide_on_mobiles height_small width_full\"><div class=\"l-section-h i-cf\"><div class=\"g-cols vc_row via_grid cols_1 laptops-cols_inherit tablets-cols_inherit mobiles-cols_1 valign_middle type_default stacking_default\"><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"font-size: 24px; color: #332463;\">Archived<\/div>\n<\/div><\/div><div class=\"w-separator size_small\"><\/div><div class=\"g-cols wpb_row via_grid cols_1 laptops-cols_inherit tablets-cols_2 mobiles-cols_2 valign_top type_default stacking_default\" style=\"--columns-gap:20px;\"><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/activity1\/\" aria-label=\"A1280-Thumbnail01\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail01-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Extending Treatment Durability With Next-Generation nAMD Therapies\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail01-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail01-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail01.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"line-height: 130%; margin-bottom: 37px;\"><u><a href=\"https:\/\/www.eye-connect.org\/namd\/activity1\/\" target=\"_blank\" rel=\"noopener\">Extending Treatment Durability With Next-Generation nAMD Therapies<\/a> <\/u><\/p>\n<p style=\"line-height: 120%; margin-top: 30px;\">Webinar<br \/>\nCredit Hours: 0.50 (30 min)<br \/>\n<span style=\"font-size: 14px; color: #ff0000; line-height: 120%;\">This activity has expired and is no longer available for credit<\/span><\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/activity1\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><\/div><div class=\"g-cols wpb_row via_grid cols_1 laptops-cols_inherit tablets-cols_2 mobiles-cols_2 valign_top type_default stacking_default\" style=\"--columns-gap:20px;\"><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/accredited-activity-2-advances-in-imaging-namd\/\" aria-label=\"A1280-Thumbnail02\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail02-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Advances in Imaging nAMD and Approaches to Use of Long-Acting Anti-VEGF Therapies\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail02-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail02-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail02.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"margin-bottom: 20px; line-height: 130%;\"><u><a href=\"https:\/\/www.eye-connect.org\/namd\/accredited-activity-2-advances-in-imaging-namd\/\" target=\"_blank\" rel=\"noopener\">Advances in Imaging nAMD and Approaches to Use of Long-Acting Anti-VEGF Therapies<\/a><\/u><\/p>\n<p style=\"line-height: 120%;\">Infographic<br \/>\nCredit Hours: 0.50 (30 min)<br \/>\n<span style=\"font-size: 14px; color: #ff0000;\">This activity has expired and is no longer available for credit<\/span><\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/accredited-activity-2-advances-in-imaging-namd\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><\/div><div class=\"g-cols wpb_row via_grid cols_1 laptops-cols_inherit tablets-cols_2 mobiles-cols_2 valign_top type_default stacking_default\" style=\"--columns-gap:20px;\"><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/adherence-persistence-with-durable-anti-vegf-therapies-for-namd\/\" aria-label=\"A1280-Thumbnail03\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail03-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Improving Adherence and Persistence With Durable Anti-VEGF Therapies for nAMD\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail03-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail03-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail03.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"line-height: 130%; margin-bottom: 37px;\"><a href=\"https:\/\/www.eye-connect.org\/namd\/adherence-persistence-with-durable-anti-vegf-therapies-for-namd\/\" target=\"_blank\" rel=\"noopener\"><u>Improving Adherence and Persistence With Durable Anti-VEGF Therapies for nAMD<\/u><\/a><\/p>\n<p style=\"line-height: 120%; margin-top: 30px;\">Case Consult<br \/>\nCredit Hours: 0.25 (15 min)<br \/>\n<span style=\"font-size: 14px; color: #ff0000; line-height: 120%;\">This activity has expired and is no longer available for credit<\/span><\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/adherence-persistence-with-durable-anti-vegf-therapies-for-namd\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><\/div><div class=\"g-cols wpb_row via_grid cols_1 laptops-cols_inherit tablets-cols_2 mobiles-cols_2 valign_top type_default stacking_default\" style=\"--columns-gap:20px;\"><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/dosing-strategy-anti-vegf-therapy-for-namd\/\" aria-label=\"A1280-Thumbnail04\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail04-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"When to Start, When to Switch, and Dosing Strategy With Anti-VEGF Therapy\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail04-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail04-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail04.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"margin-bottom: 37px; line-height: 130%;\"><a href=\"https:\/\/www.eye-connect.org\/namd\/dosing-strategy-anti-vegf-therapy-for-namd\/\" target=\"_blank\" rel=\"noopener\"><u>When to Start, When to Switch, and Dosing Strategy With Anti-VEGF Therapy<\/u><\/a><\/p>\n<p style=\"line-height: 120%; margin-top: 30px;\">Case Consult<br \/>\nCredit Hours: 0.25 (15 min)<br \/>\n<span style=\"font-size: 14px; color: #ff0000; line-height: 120%;\">This activity has expired and is no longer available for credit<\/span><\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/dosing-strategy-anti-vegf-therapy-for-namd\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/section><section class=\"l-section wpb_row hide_on_default hide_on_laptops hide_on_tablets hide_on_mobiles height_auto\"><div class=\"l-section-h i-cf\"><div class=\"g-cols vc_row via_grid cols_2 laptops-cols_inherit tablets-cols_inherit mobiles-cols_1 valign_top type_default stacking_default\"><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-separator size_custom\" style=\"height:15px\"><\/div><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/activity1\/\" aria-label=\"A1280-Thumbnail01\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail01-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Extending Treatment Durability With Next-Generation nAMD Therapies\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail01-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail01-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail01.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"line-height: 130%; margin-bottom: 37px;\"><u><a href=\"https:\/\/www.eye-connect.org\/namd\/activity1\/\" target=\"_blank\" rel=\"noopener\">Extending Treatment Durability With Next-Generation nAMD Therapies<\/a> <\/u><\/p>\n<p style=\"line-height: 120%; margin-top: 30px;\">Webinar<br \/>\nCredit Hours: 0.50 (30 min)<br \/>\n<span style=\"font-size: 14px; color: #ff0000; line-height: 120%;\">This activity has expired and is no longer available for credit<\/span><\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/activity1\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"w-separator size_custom\" style=\"height:15px\"><\/div><div class=\"w-image align_none\"><a target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/accredited-activity-2-advances-in-imaging-namd\/\" aria-label=\"A1280-Thumbnail02\" class=\"w-image-h\"><img decoding=\"async\" width=\"405\" height=\"306\" src=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail02-405x306.png\" class=\"attachment-us_405_401 size-us_405_401\" alt=\"Advances in Imaging nAMD and Approaches to Use of Long-Acting Anti-VEGF Therapies\" loading=\"lazy\" srcset=\"https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail02-405x306.png 405w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail02-300x227.png 300w, https:\/\/www.eye-connect.org\/namd\/wp-content\/uploads\/2025\/05\/A1280-Thumbnail02.png 500w\" sizes=\"auto, (max-width: 405px) 100vw, 405px\" \/><\/a><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><div style=\"border: thin solid #aea5c1; padding: 7px;\">\n<p style=\"margin-bottom: 37px; line-height: 130%;\"><u><a href=\"https:\/\/www.eye-connect.org\/namd\/accredited-activity-2-advances-in-imaging-namd\/\" target=\"_blank\" rel=\"noopener\">Advances in Imaging nAMD and Approaches to Use of Long-Acting Anti-VEGF Therapies<\/a><\/u><\/p>\n<p style=\"line-height: 120%;\">Infographic<br \/>\nCredit Hours: 0.50 (30 min)<br \/>\n<span style=\"font-size: 14px; color: #ff0000;\">This activity has expired and is no longer available for credit<\/span><\/p>\n<\/div>\n<\/div><\/div><div class=\"w-separator size_custom\" style=\"height:10px\"><\/div><div class=\"w-btn-wrapper align_center\"><a class=\"w-btn us-btn-style_6\" target=\"_blank\" href=\"https:\/\/www.eye-connect.org\/namd\/accredited-activity-2-advances-in-imaging-namd\/\"><span class=\"w-btn-label\">VIEW DETAILS<\/span><\/a><\/div><\/div><\/div><\/div><\/div><\/section>\n","protected":false},"excerpt":{"rendered":"New Anti-VEGF Therapies for Neovascular Age-related Macular Degeneration This American Academy of Ophthalmology collection of activities provides ophthalmologists with a focused update on the latest data surrounding long-acting intravitreal anti-vascular endothelial growth factor (VEGF) therapies for neovascular age-related macular degeneration (nAMD). Click on the activities below to explore valuable insights and clinical decision-making around: Therapy...","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"class_list":["post-943","page","type-page","status-publish","hentry"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.eye-connect.org\/namd\/wp-json\/wp\/v2\/pages\/943","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.eye-connect.org\/namd\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.eye-connect.org\/namd\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.eye-connect.org\/namd\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.eye-connect.org\/namd\/wp-json\/wp\/v2\/comments?post=943"}],"version-history":[{"count":172,"href":"https:\/\/www.eye-connect.org\/namd\/wp-json\/wp\/v2\/pages\/943\/revisions"}],"predecessor-version":[{"id":2026,"href":"https:\/\/www.eye-connect.org\/namd\/wp-json\/wp\/v2\/pages\/943\/revisions\/2026"}],"wp:attachment":[{"href":"https:\/\/www.eye-connect.org\/namd\/wp-json\/wp\/v2\/media?parent=943"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}